✨ Free AI Report
Biosynex SA: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Biosynex SA
Company Research

Biosynex SA: Business Overview, Financials & Competitive Analysis

Biosynex SA scores 4/10 on the AskCyborg Cyborg Score (Mixed). Growth-stage European diagnostics player with solid revenue trajectory but struggling margins; consolidation or restructuring likely pathway forward. Biosynex demonstrates revenue growth (8.81% YoY to €101.17M in 2024) but faces significant profitability challenges with €43.33M losses. While the company maintains a diversified business model and established market position in rapid diagnostics.

What is Biosynex SA's industry? Biosynex SA (biosynex.com) operates in In-Vitro Diagnostics / Medical Devices. AskCyborg classifies Biosynex SA under In-Vitro Diagnostics / Medical Devices in its company registry.

Biosynex is a French diagnostics company specializing in the design, manufacture, and distribution of rapid diagnostic tests (RDTs) and in-vitro diagnostic (IVD) products. The company serves healthcare professionals, ...

4/ 10Mixed

Cyborg Score thesis

Growth-stage European diagnostics player with solid revenue trajectory but struggling margins; consolidation or restructuring...

Read the full analyst-debate transcript →
Industry In-Vitro Diagnostics / Medical Devices
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Biosynex SA Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Biosynex SA

AskCyborg analysts argue the bull and bear cases for Biosynex SA across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Biosynex SA OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Biosynex SA Overview

Pro stress-test →

Biosynex is a French diagnostics company specializing in the design, manufacture, and distribution of rapid diagnostic tests (RDTs) and in-vitro diagnostic (IVD) products. The company serves healthcare professionals, laboratories, and patients globally, with particular focus on tropical diseases, infectious diseases, autoimmunity, and emergency markers. It represents a mid-cap player in the global rapid diagnostics market with diversified product offerings beyond core RDTs.

Strategic Profile

Pro stress-test →

Biosynex operates through multiple revenue streams including proprietary diagnostic manufacturing, distribution of third-party diagnostics, R&D services, licensing, and ancillary products (thermometers, blood pressure monitors). The company maintains strong domestic positioning with 56.5% of revenue from France and has developed a comprehensive product portfolio spanning bacteriology, parasitology, mycology, virology, and women's health. Its acquisition-friendly profile (as evidenced by past M&A activity) positions it as a consolidation target in the fragmented European diagnostics space.

Competitive Landscape

Pro stress-test →

Biosynex operates in the fragmented rapid diagnostics market alongside larger multinational players (Abbott, Roche, Siemens Healthineers) and specialized competitors (bioMérieux, Chembio Diagnostics). The company's strength lies in niche therapeutic areas (tropical diseases, emergency markers) and European market proximity rather than scale advantages. Recent partnerships with entities like Chembio Diagnostics suggest a hybrid model balancing proprietary products with third-party distribution.

Industry Context

Biosynex SA operates in In-Vitro Diagnostics / Medical Devices.

Key facts

Founded: 1993 · Headquarters: Illkirch-Graffenstaden, France · Employees: 454 · Revenue: €101.2M · Market cap: €141.5M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Biosynex SA.

  • Revenue growth accelerating: €101.17M in 2024 (+8.81% YoY) despite profitability headwinds, suggesting core demand remains intact
  • Profitability crisis: Net losses of €43.33M in 2024 represent material deterioration, indicating operational execution or margin compression challenges
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • July 2024FDA awarded "Breakthrough Device" status to Chembio Diagnostic Systems' DPP Syphilis TnT, a Biosynex partnership product
  • Q2 2024Second quarter performance described as "more challenging" suggesting deceleration in business momentum
  • +1 moreTrack every material event for Biosynex SA as it happens. Explore monitoring →
Get alerted when Biosynex SA has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Rapid Diagnostic TestsGlobal leader in rapid point-of-care diagnostics with extensive RDT portfolio→Molecular & RDT DiagnosticsFrench diagnostics leader with strength in microbiology and IVD testing→Point-of-Care & IVD ProductsUS-based rapid diagnostic specialist with focus on infectious disease testing→

Compare Biosynex SA with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Biosynex SA operates in In-Vitro Diagnostics / Medical Devices. See how the rest of the sector scores on the Cyborg framework.

Browse In-Vitro Diagnostics / Medical Devices research →
NEW · MCP server

Ask your AI assistant about Biosynex SA

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Biosynex SA and its top competitor on Cyborg Score”
“What did Biosynex SA do this quarter?”
“Is Biosynex SA a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Biosynex SA do?+
Biosynex is a French diagnostics company specializing in the design, manufacture, and distribution of rapid diagnostic tests (RDTs) and in-vitro diagnostic (IVD) products. The company serves healthcare professionals, ...
What is Biosynex SA's Cyborg Score?+
Biosynex SA has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Biosynex SA's main competitors?+
Named competitors include Rapid Diagnostic Tests, Molecular & RDT Diagnostics, Point-of-Care & IVD Products. The full competitive landscape is in the AskCyborg report.
How can I get the full Biosynex SA research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Biosynex SA research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Biosynex SA over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More In-Vitro Diagnostics research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7DiaSorin S.p.A.7Shenzhen New Industries Biomedical Engineering Co., Ltd.